Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Blood (2024) 144 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2024-205959

Published: 2024

Journal Articles

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2023-184911

Published: 2023

Journal Articles

Deciphering the Epigenetic Landscape in Histiocytic Neoplasms

Mali Salmon-Divon, Refael Meyuchas, Jamal Benhamida, Ofer Shpilberg, Roei D. Mazor, Mariko Yabe, Kseniya Petrova-drus, Omar Abdel-Wahab, Eli L. Diamond, Oshrat Hershkovitz-Rokah

Blood (2023) 142 (Supplement 1): 1161.

https://doi.org/10.1182/blood-2023-185965

Published: 2023

Journal Articles

Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease

Gaurav Goyal, Anne Reiner, Dana Bossert, Allison Sigler, Justin Buthorn, Mario Lacouture, Veronica Rotemberg, Jasmine H Francis, Ronald S. Go, Raajit K. Rampal, Eli L. Diamond

Blood (2023) 142 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2023-184879

Published: 2023

Journal Articles

Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms

Eli L. Diamond, Benjamin Durham, Ahmet Dogan, Mariko Yabe, Kseniya Petrova-Drus, Raajit K. Rampal, Raajit K. Rampal, Gary Ulaner, Mario Lacouture, Veronica Rotemberg, Anne Covey, Lynn Brody, Omar Abdel-Wahab

Blood (2023) 142 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2023-187508

Published: 2023

Journal Articles

Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients

Blood (2023) 142 (13): 1167–1171.

https://doi.org/10.1182/blood.2023020569

Published: 2023

Includes: Supplemental data

Journal Articles

RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients

Benjamin H Durham, Michael E Singer, Salima Benbarche, Caroline Erickson, Jahan Rahman, David B. Solit, Matthew Witkowski, Neal Rosen, Omar Abdel-Wahab, Eli L Diamond

Blood (2022) 140 (Supplement 1): 1098–1100.

https://doi.org/10.1182/blood-2022-163575

Published: 2022

Journal Articles

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

Gaurav Goyal, Abdellatif Tazi, Ronald S. Go, Karen L. Rech, Jennifer L. Picarsic, Robert Vassallo, Jason R. Young, Christian W. Cox, Jan Van Laar, Michelle L. Hermiston, Xin-Xin Cao, Polyzois Makras, Gregory Kaltsas, Julien Haroche, Matthew Collin, Kenneth L. McClain, Eli L. Diamond, Michael Girschikofsky

Blood (2022) 139 (17): 2601–2621.

https://doi.org/10.1182/blood.2021014343

Published: 2022

Includes: Supplemental data

Journal Articles

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

Paul G. Kemps, Jennifer Picarsic, Benjamin H. Durham, Zofia Hélias-Rodzewicz, Laura Hiemcke-Jiwa, Cor van den Bos, Marianne D. van de Wetering, Carel J. M. van Noesel, Jan A. M. van Laar, Robert M. Verdijk, Uta E. Flucke, Pancras C. W. Hogendoorn, F. J. Sherida H. Woei-A-Jin, Raf Sciot, Andreas Beilken, Friedrich Feuerhake, Martin Ebinger, Robert Möhle, Falko Fend, Antje Bornemann, Verena Wiegering, Karen Ernestus, Tina Méry, Olga Gryniewicz-Kwiatkowska, Bozenna Dembowska-Baginska, Dmitry A. Evseev, Vsevolod Potapenko, Vadim V. Baykov, Stefania Gaspari, Sabrina Rossi, Marco Gessi, Gianpiero Tamburrini, Sébastien Héritier, Jean Donadieu, Jacinthe Bonneau-Lagacherie, Claire Lamaison, Laure Farnault, Sylvie Fraitag, Marie-Laure Jullié, Julien Haroche, Matthew Collin, Jackie Allotey, Majid Madni, Kerry Turner, Susan Picton, Pasquale M. Barbaro, Alysa Poulin, Ingrid S. Tam, Dina El Demellawy, Brianna Empringham, James A. Whitlock, Aditya Raghunathan, Amy A. Swanson, Mariko Suchi, Jon M. Brandt, Nabeel R. Yaseen, Joanna L. Weinstein, Irem Eldem, Bryan A. Sisk, Vaishnavi Sridhar, Mandy Atkinson, Lucas R. Massoth, Jason L. Hornick, Sanda Alexandrescu, Kee Kiat Yeo, Kseniya Petrova-Drus, Stephen Z. Peeke, Laura S. Muñoz-Arcos, Daniel G. Leino, David D. Grier, Robert Lorsbach, Somak Roy, Ashish R. Kumar, Shipra Garg, Nishant Tiwari, Kristian T. Schafernak, Michael M. Henry, Astrid G. S. van Halteren, Oussama Abla, Eli L. Diamond, Jean-François Emile

Blood (2022) 139 (2): 256–280.

https://doi.org/10.1182/blood.2021013338

Published: 2022

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Ran Weissman, MSc, Nir Pilar, MD, Benjamin H Durham, MD BS, Michelle Ki, BSc, Roei D Mazor, MD, Omar I Abdel-Wahab, MD, Noam Shomron, PhD, Ofer Shpilberg, MD MPH, Eli L Diamond, MD, Oshrat Rokah, PhD

Blood (2018) 132 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2018-99-112388

Published: 2018

Journal Articles

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Benjamin H Durham, MD BS, Estibaliz Lopez-Rodrigo, MD, David H Abramson, MD, Jennifer Picarsic, MD, Alessandro Pastore, Diana Mandelker, MD PhD, Michael Francis Walsh, MD, Maria E Arcila, MD, Marc Ladanyi, MD, David Solit, MD, Michael F. Berger, PhD, David M. Hyman, MD, Michelle Ki, BSc, Ira Dunkel, MD, Frederic Geissmann, MD PhD, Eli L Diamond, MD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 49.

https://doi.org/10.1182/blood-2018-99-114248

Published: 2018

Journal Articles

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

Oussama Abla, Eric Jacobsen, Jennifer Picarsic, Zdenka Krenova, Ronald Jaffe, Jean-Francois Emile, Benjamin H. Durham, Jorge Braier, Frédéric Charlotte, Jean Donadieu, Fleur Cohen-Aubart, Carlos Rodriguez-Galindo, Carl Allen, James A. Whitlock, Sheila Weitzman, Kenneth L. McClain, Julien Haroche, Eli L. Diamond

Blood (2018) 131 (26): 2877–2890.

https://doi.org/10.1182/blood-2018-03-839753

Published: 2018

Journal Articles

Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 794.

https://doi.org/10.1182/blood.V130.Suppl_1.794.794

Published: 2017

Journal Articles

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

Eli L Diamond, MD, Benjamin H Durham, MD BS, Ahmet Dogan, MD PhD, David M. Hyman, MD, Raajit K. Rampal, MD PhD, Gary Ulaner, MD, Lynn Brody, MD, Omar Abdel-Wahab, MD

Blood (2017) 130 (Supplement 1): 257.

https://doi.org/10.1182/blood.V130.Suppl_1.257.257

Published: 2017

Journal Articles

Erdheim-Chester disease: the “targeted” revolution

Augusto Vaglio, Eli L. Diamond

Blood (2017) 130 (11): 1282–1284.

https://doi.org/10.1182/blood-2017-07-795054

Published: 2017

Journal Articles

High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis

Blood (2017) 130 (8): 1007–1013.

https://doi.org/10.1182/blood-2017-01-761718

Published: 2017

Includes: Supplemental data

Journal Articles

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults

Paul Milne, Venetia Bigley, Chris M. Bacon, Antoine Néel, Naomi McGovern, Simon Bomken, Muzlifah Haniffa, Eli L. Diamond, Benjamin H. Durham, Johannes Visser, David Hunt, Harsha Gunawardena, Mac Macheta, Kenneth L. McClain, Carl Allen, Omar Abdel-Wahab, Matthew Collin

Blood (2017) 130 (2): 167–175.

https://doi.org/10.1182/blood-2016-12-757823

Published: 2017

Includes: Supplemental data

Journal Articles

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells

Blood (2017) 130 (2): 176–180.

https://doi.org/10.1182/blood-2016-12-757377

Published: 2017

Includes: Supplemental data

Journal Articles

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Blood (2016) 128 (22): 480.

https://doi.org/10.1182/blood.V128.22.480.480

Published: 2016

NARROW

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Deciphering the Epigenetic Landscape in Histiocytic Neoplasms

Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease

Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms

Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients

RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

Erdheim-Chester disease: the “targeted” revolution

High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only